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Abstract  
Nowadays various techniques have been applied for the improvement of physicochemical properties such as 
solubility, bioavailability, stability and hygroscopic nature of pharmaceutical solids without effecting the 
biochemical composition of the active pharmaceutical ingredients (API). Supramolecular approach specially 
the crystal engineering technique is one of the best techniques which play an important role to improve the 
physico-chemical, thermal and mechanical properties of drug molecules. Crystal engineering approach offers a 
number of routes such as co-crystallization, polymorphism, hydrate and salt formation with the help of which 
drug molecules with good physico-chemical behavior can be prepared. This article covers the concept of 
supramolecular chemistry and crystal engineering approach for the preparation of co-crystals and their 
application in pharmaceutical industries. 
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Introduction 
Molecules generally exist either in solid, liquid or gaseous forms and also some meta-stable stages 
such as semi-solid or semi–liquid under a certain set of conditions. Solid organic or inorganic 
compounds are found to be existed either in crystalline or amorphous form. Many solid organic or 
inorganic compounds, organo-metallic complexes exhibit themselves as biologically active 
molecules and few of them can be treated as drug molecules for particular diseases after long 
investigation. These solids are then considered as pharmaceutical solids. A finished pharmaceutical 
product (FPP) has direct effect in the diagnosis, mitigation, treatment and prevention of disease. A 
pharmaceutical product will be considered as a active pharmaceutical ingredient (API) [1] if they 
will not destroy the physiological functions in human being during application or functioning. 
Active pharmaceutical ingredients of a drug molecule are generally delivered to the patient in the 
stable solid format either in the form of a tablet or capsule. In these capsules or tablets the solid 
APIs are kept in several distinct forms such as co-crystals, polymorphs, solvates, hydrates, salts and 
amorphous solids according to requirement in order to increase the physicochemical properties 
such as bioavailability, purity, stability and also good performing ability of the drug molecule [2]. 
The design and synthesis of active pharmaceutical solids by  understanding and controlling the 
solid-state chemistry without effecting the functional properties of  pure drug substances in the 
formulated products, is therefore a challenging job in the drug development process. The concept of 
supramolecular chemistry and crystal engineering can provide valuable idea for designing and 
synthesizing such active pharmaceutical solids in approved dosage form. 
 Supramolecular chemistry 
The concept of bond formation between atoms by sharing the electron pair between themselves and 
the concept of hybridization created enormous interest among the chemists for synthesizing new 
molecules with useful properties. The development of synthetic organic chemistry or covalent 
synthesis started with the synthesis of urea by Friedrich Wöhler in 1828 [3].Thereafter many 
efficient and important methodologies have been evolved in a galloping manner for synthesizing 
novel and complex molecules by making and breaking bonds in a controlled and precise fashion. 
Beyond molecular chemistry, there lies another field of chemistry based on non-covalent 
interactions which is popularly known as supramolecular chemistry. The concept and the term of 
supramolecular chemistry were first introduced by Jean Marie Lehn in 1978. J. M. Lehn defined it 
as, “Just as there is a field of molecular chemistry based on covalent bond, there is a field of 
supramolecular chemistry, the chemistry of molecular assemblies and of the intermolecular bond” 
[4].The field of supramolecular chemistry was started with the discovery of chlorine hydrate by Sir 
Humphry Davy in 1810. After the discovery of “lock and key” principle [5] by Sir Emil Fischer in 
1894 and the concept of receptor introduced by Paul Ehrlich in 1906, supramolecular chemistry 
started expanding fast and within a short period it had emerged as a major area of research due to 
its multidisciplinary nature and applicative aspects ranging from biology to material science. 
Donald J. Cram [6], Jean-Marie Lehn [7], and Charles J. Pedersen [8] were awarded the Nobel Prize 
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for Chemistry in 1987 for their work on molecular recognition (selectively binding of guest 
molecules) based on cyclic crown ethers and cryptands in the area of host-guest chemistry. The key 
concept of Supramolecular Chemistry lies in the directionality and strength of various kinds of 
non-covalent interactions such as hydrogen bonding, van der Waals force, electrostatic interaction 
etc. The intermolecular forces of interactions are responsible for different states of compounds such 
as solid, liquid and gas. The objects of supramolecular chemistry are the formation of 
supermolecules and other polymolecular entities that result from the spontaneous association of a 
large number of components into a specific phase (membranes, vesicles, micelles, solid state 
structures etc.) (McNaught et al.,1997). The solid-state structures in supramolecular field are again 
classified into polymorphs, salts, co-crystals, amorphous and solvates amorphous which are the 
important forms for APIs used in drug molecules (Figure 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Schematic representation of the structures of solid forms of APIs.  
 
Several studies have been carried out to date to understand the nature of such interactions using 
various spectroscopic techniques. The study of such recognition or self-assembling events of 
molecules in the solid state (crystalline form especially single crystal) has been regarded as crystal 
engineering, which uses X-ray crystallography as a major tool for characterization.  
Crystal engineering 
The term “Crystal Engineering” was first proposed by Pepinsky [9] in 1955 and von. Hippel [10] 
highlighted it in 1962 in his paper in Science. In 1971, the term, “crystal engineering” gained 
importance when G. M. J. Schmidt [11]  used it for explaining the packing principles of organic 
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molecules. The “Crystal Engineering” is defined by G. R. Desiraju [12] as “the understanding of 
intermolecular interactions in the context of crystal packing and in the utilization of such 
understanding in the design of new solids with desired physical and chemical properties”. The 
process of crystallization deals with the aggregation of millions of molecules through non-covalent 
interactions. Therefore, Dunitz [13] defined crystals as “supermolecules par excellence.” The 
fundamental concepts of supramolecular chemistry and crystal engineering are same as both deals 
with the precise and controlled aggregation of molecules via non-covalent interactions [14]. One of 
the important features of crystal engineering is to generate or recognize proper synthon which 
ensures the predictability one, two, three- dimensional networks during aggregation of molecules 
through non-covalent interaction. 
Smaller building units are the fundamental and essential tools for synthesizing both covalently 
bonded complex organic molecules and non-covalently bonded supramolecular architectures. In 
1967, E. J. Corey introduced concept of “synthon” which is the root for the synthesis of targeted 
organic molecule [15]. Corey defined synthons as “structural units within molecules which can be 
formed and/or assembled by known or conceivable synthetic operations”. Similarly, for designing 
predictable supramolecular architectures via crystal engineering technique, identification of proper 
synthon is essential. Therefore, the term “Supramolecular Synthon” was introduced by G. R. 
Desiraju in 1995 in the context of supramolecular synthesis [16]. He defined supramolecular 
synthons as “structural units within supermolecules which can be formed and/or assembled by 
known or conceivable synthetic operations involving intermolecular interactions”. Supramolecular 
synthons via conventional hydrogen bonds are the most popular and commonly used but 
supramolecular synthons involving weak interactions such as π···π interactions, halogen-halogen 
interactions, cation···π and anion···π interactions also play a major role in assembling the 
molecules in the solid state. 
Generally the synthons that are formed between same functional group of one chemical 
component are termed as homomeric synthons. The hydrogen bonded homosynthon of –COOH 
group is found in the crystal structure of the dimmers of different carboxylic acid compounds. 
Some example of homomeric synthons are shown in the scheme 1. 
 
 
 
 
 
 
 
 
 
Scheme1 Hydrogen bonded homomeric synthons. 
   
Heteromeric synthons are formed between same or different functional groups of two or more 
chemical components. The well known examples are acid-pyridine, acid-amide, amide-pyridine and 
pyridine-hydroxyl etc (Scheme 2). 
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Scheme 2 Hydrogen bonded heteromeric synthons. 
 
The rational design and prediction of structures in solid state with the help of proper synthons 
formation are the main objectives of crystal engineering. There are several crystal engineering 
techniques for designing predictable single crystals such as slow evaporation after dissolving the 
functional materials in proper solvent system, bi-layer technique, seeding technique and vapor 
diffusion technique.  All these techniques are very important for the synthesis of co-crystals in 
order to increase the physico-chemical properties of APIs. 
 Co-crystal 
Aakeröy defined co-crystals as the aggregation of two molecules in the crystalline form at ambient 
conditions [17]. In 2007, G.P Stahly modified the definition of co-crystals as, “Co-crystals consist 
of two or more components that form a unique crystalline structure having unique properties” [18]. 
Zaworotko defined co-crystal as ‘A co-crystal is a multiple component crystal in which all 
components are solid under ambient conditions when in their pure form. These components co-exist 
as a stoichiomeric ratio of a target molecule or ion and a neutral molecular co-crystal former(s)’ 
[19]. Co-crystals are designed based on the principles of the supramolecular synthesis; it provides a 
powerful approach for proactive discovery of novel pharmaceutical solid phases. Co-crystals 
consist of multiple components at defined stoichiometric ratios, where different molecular species 
interact by hydrogen bonding and other non-covalent interactions. Co-crystals can have different 
properties than the crystals of individual components. A very early example of a co-crystal is the 
1:1 molecular complex between benzoquinone and hydroquinone, named quinhydrone, reported by 
Wöhler in 1844. It is the first crystal structure of a co-crystal in the Cambridge Structural Database 
(CSD) [20] with reported coordinates for two polymorphic forms, a monoclinic form (P21/c, 
QUIDON02) and a triclinic form (P-1, QUIDON). The use of hydrogen bonding rules, synthons 
and graph sets may assist in the design and analysis of co-crystal systems. Etter and co-workers 
proposed the guidelines to facilitate the deliberate design of hydrogen-bonded solids [21]. 
According to Etters rule, (i) all good proton donors and acceptors are used in hydrogen bonding, (ii) 
six-membered ring intramolecular hydrogen bonds form in preference to intermolecular hydrogen 
bonds and (iii) the best proton donor and acceptor remaining after intramolecular hydrogen bond 
formation will form intermolecular hydrogen bonds to one another (but not all acceptors will 
necessarily interact with donors). 
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 Pharmaceutical co-crystals 
In 2011, Qiao defined pharmaceutical co-crystals as a multiple component crystals in which one of 
the co-crystal components act as an API and the rest components are called conformers. The 
multi-component molecular assemblies by employing the supramolecular and crystal engineering 
concept opens a new arena in the field of pharmaceutical industries for developing targeted drug 
molecules with desired physical and chemical properties (Table 1). In 2007, Trask mentioned that 
co-crystals may enhance a large number of essential parameters including chemical stability, 
hygroscopicity, compressibility and flow ability in addition to potential improvements in solubility, 
bioavailability, and physical stability of pharmaceutical solids. So co-crystals can be recognized as 
an attractive alternative for solid forms of drug products. 
Table 1 Recent case studies of Pharmaceutical co-crystals 
 
API CONFORMER PREPARATION 
METHOD 
IMPROVED 
PROPERTY 
REFERENCE 
Theophylline  Nicotinamide Solvent evaporation Solubility Lu  et al 2009 
 
 Sulphamethazine 
 
Theophylline 
 
Solvent evaporation 
 
Thermal stability,  
Spectroscopic and 
X-ray diffraction 
properties 
 
Lu  et al 2011 
  
Sulphamethazine 
 
Aspirin, 
Benzoic acid, 
Trimethoprim, 
4-Amino salicylic acid 
 
Solvent evaporation 
 
Physical stability 
 
Caira et al 2007 
 
Piroxicam 
 
Saccharin 
 
Solvent evaporation 
 
Physical stability 
 
Childs et al 
2007 
 
 Carbamazepine 
 
Nicotinamide, 
Saccharin 
 
Cooling 
crystallization 
 
Physical stability 
Dissolution rate and 
Oral Bio-availability 
 
Hickey et al    
2007 
 
   Aspirin 
 
4,4'-bipyridine 
 
Slurry Conversion 
 
Physical stability 
 
Walsh  et al 
2003 
 
Indomethacin 
 
     Saccharin 
 
Solvent evaporation 
or solvent assisted 
grinding 
 
 Physical stability  
 and dissolution rate 
 
Basavoju et al 
2008 
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 Norfloxacin 
     
    Isonicotinamide 
    Succinic acid  
    Malonic acid 
    Maleic acid 
 
Solvent evaporation 
 
Solubility 
 
Basavoju et al 
2006 
 
Ibuprofen 
 
4,4'-dipyridyl-nicotinamide 
 
Solvent evaporation 
 
Solubility 
 
Walsh et al 
2003 
 
Paracetamol 
4,4'-bipyridine Solvent evaporation Physical stability  
and dissolution rate 
 
Walsh et al 
2003 
Flubiprofen 4,4'-bipyridine Solvent evaporation Physical stability Oberoi et al 
2005 
 
Acetaminophen 
 
Pyridine-2,4-dicarboxylic 
acid 
Solution mediated 
phase transfer 
technique 
 
Physical stability 
 
Sander et al 
2010 
 
Itraconazole 
 
Malic acid 
Tartaric acid 
Succinic acid 
 
Solvent evaporation 
 
Improved dissolution 
rate 
 
Remenar et al 
2003 
 
Caffeine 
 
Maleic acid  
Gluteric acid 
 
Solution mediated 
phase transfer 
technique 
 
Physical stability 
 
Guo et al 2010 
Yu et al 2010 
 
Fluoxetine 
hydrochloride 
 
Benzoic acid  
Fumaric acid 
Succinic acid 
 
Solvent evaporation 
 
Intrinsic dissolution 
rate 
 
Childs et al 
2004 
 
Theophylline contains hydrogen bonding donor and acceptor functionalities such as O-H and 
N-H sites which are also the complementary functional groups of each other play effective role for 
crystal formation. Theophylline itself is often used for asthma or chronic obstructive pulmonary 
disease treatment. The physiochemical character of Theophylline is found to be increased when 
Theophylline forms co-crystal with different substrates. In 2007 Caira reported that the 
physiochemical character of Sulfamethazine drug is also increased in the co-crystal form with 
different substrates such as aspirin, benzoic acid, trimethoprim, 4-aminosalicylic acid, etc. The 
theophylline-sulfamethazine co-crystal has unique thermal, spectroscopic and X-ray diffraction 
properties, but higher hygroscopic nature than individual components (Lu et al., 2011a; Lu and 
Rohani, 2010). In 2009 Lu and Rohani reported that the theophylline–nicotinamide co-crystal in a 
1:1 molar ratio has higher solubility than theophylline itself.  
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Conclusion 
The development of new molecular complexes in the form of a solid co-crystal and their 
applications as drug materials by crystal engineering approach is becoming progressively more 
important than the other solid forms such as salts, solvates, hydrates etc due to their large extent of 
purity and several valuable physico-chemical properties. Other advantages lies in the form of 
co-crystals are co-crystals are normally non-toxic as the active sites of the interacting molecules are 
involved in hydrogen bonding and other weak interactions. Co-crystals can be easily handled for 
various applications and even the co-crystal components can be easily isolated by applying simple 
techniques. 
The design and synthesis of co-crystals in the form of API’s depend on the basic knowledge of 
Supramolecular Chemistry and the identification of directionality of growth via proper 
Supramolecular synthons formation with the help of various kinds of interactions which can be  
determined by Crystal engineering. The knowledge of crystal engineering approach plays an 
important role for raising interest to produce biologically non-hazardous and non-toxic co-crystal 
materials in the form of API’s.  
References 
1. Procedure for prequalification of pharmaceutical products. WHO Technical report Series; No. 961, 
Annex 10 
2. Schulthesis N, Newmann A. Pharmaceutical Cocrystals and their Physicochemical Properties. Cryst. 
Growth Des. 2009, 9:2950-2967 
3. Wöhler F. Ueber kunstliche Bildung des Harnstoffs. Annalen der Physik.1828, 88:253-256 
4. Lehn JM. Supramolecular Chemistry: Concepts and Perspectives. VCH: Weinheim; 1995; b) Lehn JM. 
Supramolecular Chemistry—Scope and Perspectives Molecules, Supermolecules, and Molecular Devices 
(Nobel Lecture). Angew. Chem. Int. Ed. 1988, 27:89-112 
5. Fischer E. Einfluss der konhguration auf die wirkung der enzyme. Ber. Dtsch. Chem. 1894, 3:2985-2993 
6. Cram, DJ, Cram M. Host-Guest Chemistry: Complexes between organic compounds simulate the 
substrate selectivity of enzymes. Science. 1974, 183:803-809 
7. Dietrich B, Lehn JM, Sauvage JP. Les Cryptates. Tetrahedron Lett. 1969, 10: 2889-2892 
8. Dietrich B, Lehn JM, Sauvage JP. Cryptates-XI Complexes macrobicycliques, formation, structure, 
properties. Tetrahedron. 1973, 29:1647-1658 
9. Dietrich B, Lehn JM, Sauvage JP, Blanzat J. Cryptates-X Synthesis et proprieties physiques de systems 
diaza-polyoxa-macrobicycliques. Tetrahedron. 1973, 29:1629-1645 
10. Pedersen CJ. Cyclic Polyethers and Their Complexes with Metal Salts. J. Am. Chem. Soc.1967, 89: 
7017-7036; b) Pedersen CJ. The Discovery of Crown Ethers (Noble Lecture). Angew Chem Int Ed. 1988, 
27:1021-1027 
11. Pepinsky R. Crystal Engineering: New Concepts in Crystallography. Phys Rev. 1955, 100:971-971 
12. von Hippel AR. Molecular Designing of Materials. Science. 1962, 138:91-108 
13. Schmidt GMJ. Photodimerization in the solid state. Pure Appl Chem. 1971, 27:647-678 
  
 
Ivy Union Publishing | http: //www.ivyunion.org September 26, 2014 | Volume 1 | Issue 1  
Mahata G et al. American Journal of Drug Discovery 2014, 1:1-9 Page 9 of 9 
14.  Desiraju GR. Crystal Engineering. The Design of Organic Solids; Elsevier: Amsterdam; 1989 
15.  Dunitz JD. Phase transitions in molecular crystals from a chemical viewpoint. Pure Appl. Chem. 1991, 
63:177-185 
16. Müller KD,Hobza P. Noncovalent Interactions: A Challenge for Experiment and Theory. Chem. Rev. 
2000, 100:143-167 
17. Corey EJ, Cheng XM. The Logic of Chemical Synthesis. Wiley, New York; 1995. 
18. Desiraju GR. Supramolecular Synthons in Crystal Engineering-A New Organic Synthesis. Angew. Chem. 
Int. Ed. 1995, 34:2311-2327 
19. Aakeröy CB,Salmon DJ. Building co-crystals with molecular sense and supramolecular sensibility. 
CrystEngComm. 2005, 7:439-448 
20. Stahly G P. Diversity in Single- and Multiple-Component Crystals. The Search for and Prevalence of 
Polymorphs and Cocrystals. Cryst. Growth Des. 2007, 7:1007-1026. 
21. Shan N,Zaworotko MJ. The role of cocrystals in pharmaceutical science. Drug Discovery Today. 2008, 
13:440-446 
22. a) Cambridge Crystallographic Data Center, www.ccdc.cam.ac.uk. The current release of the CSD (Ver. 
5.30, November 2008, ConQuest 1.11) contains over 450 000 entries; b) Nangia A. Supramolecular 
chemistry and crystal engineering. Curreent Trends in Science. 2005, 35-51 
23.  Etter MC. Encoding and decoding hydrogen-bond patterns of organic compounds. Acc. Chem. Res. 
1990, 23:120-126 
 
 
